SCHEMBL714867

SCHEMBL714867

CC[Hg]SOc1ccccc1C(=O)[O-].[Na+]

nearest known ligand 0.41

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
MEN1 O00255 2/20 0.36
LMNA P02545 2/20 0.36
KMT2A Q03164 2/20 0.36
NR1I2 O75469 1/20 0.36
CHRM2 P08172 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2A P08913 1/20 0.36
MAPT P10636 1/20 0.36
OPRK1 P41145 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
LTB4R Q15722 3/20 0.35
LTB4R2 Q9NPC1 3/20 0.35
TSHR P16473 1/20 0.35
HCRTR1 O43613 2/20 0.35
IRAK4 Q9NWZ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3134927 0.84 KDM4E (0.49) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL6304663 0.83 KDM4E (0.47) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL2844163 0.83 KDM4E (0.43) KDM4EALDH1A1HPGDLTB4RLTB4R2
SCHEMBL5404188 0.78 ALDH1A1 (0.42) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL5709037 0.74 HCRTR1 (0.60) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL31721706 0.74 HCRTR1 (0.60) KDM4EALDH1A1HPGDMEN1LMNA
SCHEMBL8156346 0.73 ALDH1A1 (0.43) KDM4EALDH1A1HPGDLMNAKMT2A
SCHEMBL29357453 0.73 ALDH1A1 (0.43) KDM4EALDH1A1HPGDLMNAKMT2A
SCHEMBL3525 0.73 ALDH1A1 (0.43) KDM4EALDH1A1HPGDLMNAKMT2A
Hydrochloric Acid SCHEMBL20582713 0.72 ALDH1A1 (0.42) KDM4EALDH1A1HPGDLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090169424-A1 Method of disinfecting and wetiing the interior of a building FRANCHI RICHARD MICHAEL 2009-07-02 US claimed
WO-2007117565-A9 STANDARDIZATION OF PROCESSES FOR CULTURING PRIMARY CELLS CHI SCIENT INC (US) 2007-12-27 WO claimed
WO-2007117565-A2 STANDARDIZATION OF PROCESSES FOR CULTURING PRIMARY CELLS CHI SCIENTIFIC, INC. (US) 2007-10-18 WO claimed
US-20070238175-A1 Standardization of processes for culturing primary cells CHI SCIENTIFIC, INC. 2007-10-11 US claimed
EP-1161265-A4 METHOD FOR THE IDENTIFICATION AND REMOVAL OF NITS FROM HAIR REID LORI FOX (US) 2006-01-11 EP claimed
US-6942875-B2 Applying polymerizable monomer and fungicide; applying to skins CLOSURE MEDICAL CORPORATION (US) 2005-09-13 US claimed
US-20040151688-A1 Adhesive treatment for epistaxis CLOSURE MEDICAL CORPORATION (US) 2004-08-05 US claimed
US-6767552-B2 Adhesive treatment for oral fungal infection CLOSURE MEDICAL CORPORATION 2004-07-27 US claimed
US-6602496-B2 Applying polymerizable monomer and fungicide; applying to skins CLOSURE MEDICAL CORPORATION 2003-08-05 US claimed
US-6585967-B2 Adhesive treatment for tinea cruris CLOSURE MEDICAL CORPORATION 2003-07-01 US claimed
US-5044141-A Method for sterile packaging and wetting of articles FRANCHI TECHNOLOGY CORPORATION 1991-09-03 US claimed
EP-0209192-B1 CONTACT-LENS LIQUID ICN PHARMACEUTICALS HOLLAND B.V. (NL) 1991-06-05 EP claimed
US-4715982-A NONIRRITATING L'OREAL (FR) 1987-12-29 US claimed
EP-0209192-A1 Contact-lens liquid ICN PHARMACEUTICALS HOLLAND B.V. (NL) 1987-01-21 EP claimed
EP-0053451-B1 CONTACT LENS DISINFECTING AND PRESERVING SOLUTION (POLYMERIC) BAUSCH & LOMB INCORPORATED (US) 1985-03-13 EP claimed
EP-0037043-B1 STABILISED OPHTHALMIC FORMULATION THE WELLCOME FOUNDATION LIMITED (GB) 1984-11-21 EP claimed
US-4421748-A LECITHIN AND VISCOSITY-ADJUSTING AGENT TRAGER SEYMOUR F 1983-12-20 US claimed
EP-0037043-A1 Stabilised ophthalmic formulation THE WELLCOME FOUNDATION LIMITED (GB) 1981-10-07 EP claimed
US-4252826-A CARBOXYLATE OF A METHYL POLYETHOXYLATED GLUCOSIDE AND A PRESERVATIVE AGENT L'OREAL (FR) 1981-02-24 US claimed
US-4013576-A AMPHOTERIC SURFACTANT WESLEY-JESSEN INC. (US) 1977-03-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040151688-A1 Adhesive treatment for epistaxis ICAM1, ELANE, EPCAM KDM4E 3861/4885ALDH1A1 2011/4885HPGD 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.